Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.50 |
| ▸ | SRC | P12931 | 15/20 | 0.50 |
| ▸ | KDR | P35968 | 14/20 | 0.50 |
| ▸ | ABL1 | P00519 | 13/20 | 0.50 |
| ▸ | MTOR | P42345 | 12/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.50 |
| ▸ | HCK | P08631 | 11/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.50 |
| ▸ | PRKDC | P78527 | 11/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.50 |
| ▸ | EPHB4 | P54760 | 10/20 | 0.48 |
| ▸ | LCK | P06239 | 6/20 | 0.47 |
| ▸ | BTK | Q06187 | 5/20 | 0.47 |
| ▸ | LYN | P07948 | 3/20 | 0.47 |
| ▸ | FYN | P06241 | 3/20 | 0.47 |
| ▸ | RET | P07949 | 3/20 | 0.47 |
| ▸ | TEK | Q02763 | 3/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25933940 | 1.00 | EGFR (0.50) | EGFRSRCKDRABL1MTOR | |
| SCHEMBL25933948 | 1.00 | EGFR (0.50) | EGFRSRCKDRABL1MTOR | |
| SCHEMBL25933927 | 1.00 | EGFR (0.50) | EGFRSRCKDRABL1MTOR | |
| SCHEMBL25933923 | 0.90 | SRC (0.44) | EGFRSRCKDRABL1MTOR | |
| SCHEMBL25933935 | 0.90 | SRC (0.44) | EGFRSRCKDRABL1MTOR | |
| SCHEMBL25933909 | 0.90 | SRC (0.44) | EGFRSRCKDRABL1MTOR | |
| SCHEMBL25933945 | 0.90 | SRC (0.44) | EGFRSRCKDRABL1MTOR | |
| SCHEMBL25933949 | 0.90 | SRC (0.44) | EGFRSRCKDRABL1MTOR | |
| SCHEMBL29439161 | 0.87 | BTK (0.64) | EGFRSRCKDRABL1HCK | |
| SCHEMBL22737466 | 0.87 | BTK (0.64) | EGFRSRCKDRABL1HCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | BTK, WEE1, WEE2 | EGFR 2234/4885SRC 142/4885KDR 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.